Table 1.
Patient characteristics
| Total (n = 29) | |
|---|---|
| Age (years) | 64 (40–82) |
| Sex | |
| Female | 11 (38%) |
| Male | 18 (62%) |
| Performance status | |
| 0 | 16 (55%) |
| 1 | 12 (41%) |
| 2 | 1 (3%) |
| Clinically significant concomitant disease | 19 (66%) |
| ISS stage | |
| I | 10 (34%) |
| II | 11 (38%) |
| III | 8 (28%) |
| High-risk cytogenetic aberrations t(4;16), t(14;16), del17p | 9 (31%) |
| Previous regimens | |
| Number of prior lines | 2 (1–7) |
| ≥2 prior lines | 27 (93%) |
| Autologous stem cell transplantation | 18 (62%) |
| Lenalidomide exposure | |
| Refractory | 29 (100%) |
| immediate previous line of lenalidomide therapy | 20 (69%) |
| any previous timepoint of lenalidomide therapy | 9 (31%) |
| Progressive | |
| While on lenalidomide therapy | 24 (83%) |
| Within 60 days of cessation of lenalidomide therapy | 5 (17%) |
| Median dose of lenalidomide in the last cycle prior to enrollment (mg) | 25 (10–25) |
| Lenalidomide + bortezomib exposure | |
| Exposed | 24 (83%) |
| Refractory | 10 (34%) |
Data are n (%) or median (range)